摘要
目的分析沐舒坦与溴己新治疗慢性支气管炎的临床疗效。方法选取我院儿科在2013年12月至2016年5月收治的188例慢性支气管炎患者为研究对象,将其随机分为参照组与研究组,各94例,参照组患者采取常规治疗联合溴己新进行治疗,研究组患者在参照组基础上加用沐舒坦进行治疗,比较两组患者的临床疗效,并比较两组患者在治疗中的不良反应发生情况。结果研究组患者的治疗总有效率与不良反应发生率明显优于参照组(P<0.05)。结论对慢性支气管炎患者使用沐舒坦联合溴己新进行治疗能够取得理想的临床疗效,患者的临床症状得到了有效的改善,治疗的安全性与彻底性较高,而且还能够显著降低患者发生不良反应的可能性,保护了患者的肺功能,提高了生活质量,值得在今后的临床中进行大范围的推广与应用。
Objective To analyze the clinical effect of mucosolvan combined with bromhexine on chronic bronchitis. Methods One hundred and eighty-eight cases of chronic bronchitis treated in our hospital from December 2013 to May 2013 were selected and randomly divided into control group and research group, with 94 cases in each group. The control group was treated with conventional treatment combined with bromhexine, while the research group received mucosolvan on the basis of the control group, the clinical curative effect and adverse reactions incidence of the two groups were compared. Results The total effective rate and incidence rate of adverse reactions in the research group were significantly superior to those in the control group （P〈0.05）. Conclusion For patients with chronic bronchitis, mucosolvan combined with bromhexine can achieve ideal clinical curative effect, the patient＇s clinical symptoms are improved effectively, the security and the thoroughness of treatment is very high, and it also can significantly reduce the possibility of occurrence of adverse reactions, protect patient＇s lung function, and improve patient＇s quality of life, which is worth popularization and application in future clinical with a wide range.
出处
《临床医学研究与实践》
2017年第10期51-52,共2页
Clinical Research and Practice
